IHS-TOWERS
12.4.2021 08:02:13 CEST | Business Wire | Press release
IHS Holding Limited (“IHS Towers”), one of the largest independent owners, operators and developers of shared telecommunications infrastructure in the world by tower count, has acquired Centennial Towers’ Brazilian and Colombian tower operations.
This acquisition brings an additional 602 towers in Brazil, and 217 towers in Colombia, strengthening IHS Towers’ position and core expertise in both markets. This latest transaction comes shortly after IHS Towers’ acquisition of Skysites in Brazil and is a testament to the company’s commitment to expanding its business in both Latin American markets. Centennial Towers has extensive expertise in providing mobile network operators with a wide range of infrastructure solutions including Build to Suit towers, Rooftops, Distributed Antenna Systems, Small Cells and Site Colocation & Leasing.
These recent acquisitions highlight and demonstrate the continuation of IHS Towers’ growth strategy and demonstrates its 20-year track record of growth and excellence in telecommunications infrastructure across emerging markets. IHS Towers has developed complete ecosystems around its towers including green energy, backhaul, monitoring and active equipment which will be leveraged across its new Latin American markets. This acquisition will further enhance IHS Towers’ customer offerings and ensure the company is well-positioned to support the upcoming roll-out of 5G by offering customers new locations for signal transmission and distribution, as well as supporting fiber deployment.
Sam Darwish, IHS Chairman and Group Chief Executive Officer , said: “Following our recent acquisition of Skysites in Brazil, I am delighted to announce the acquisition of a third Latin American tower operator. The addition of Centennial Towers’ Brazilian and Colombian operations adds scale to our IHS Towers Latin American portfolio and will further strengthen the deep expertise and solutions we can offer to current and potential customers in these markets. Latin America remains a key region for us with its high growth potential and, through these transactions, we will continue to increase our market presence and build on the momentum sparked by our initial entry into the region last year with the acquisition of Cell Site Solutions.”
Steven Moskowitz, Chief Executive Officer, Centennial Towers, said: “We are thrilled to enter into this transaction with IHS Towers as they recognize the uniqueness of Centennial’s diverse asset base in these two countries, which are primed for high levels of growth due to their strategic locations and quality construction. Centennial’s strong client relationships and proprietary management information systems will assist IHS Towers in advancing their drive to significantly increasing footprint and colocation growth in Latin America for years to come.”
About IHS: IHS is one of the largest independent owners, operators and developers of shared telecommunications infrastructure in the world by tower count, with more than 29,700 towers across nine markets. IHS continues to grow and develop its existing positions and offerings in Brazil, Cameroon, Colombia, Côte d’Ivoire, Kuwait, Nigeria, Peru, Rwanda and Zambia. For more information, please email: communications@ihstowers.com or visit: www.ihstowers.com
About Centennial Towers: Centennial Towers is an independent developer, owner and operator of wireless communications towers in Latin America, with current operations in Mexico consisting of approximately 800 towers. For more information, please visit: www.centennialsites.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210411005041/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom